人尿激肽原酶治疗急性脑梗死的临床效果与影响因素的相关性分析

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1515 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of human urinary kallikrein(HUK) on acute cerebral infarction and the relationship between the treatment result and influential factors. Methods: One hundred and twenty patients with acute cerebral infarction were enrolled in the randomized control trail.All patients were randomly divided into treatment group(n=60) and control group(n=60).They were both treated by identical basis therapy.The patients in the treatment group were treated by syringe pumps of 0.15 PNA HUK diluted in 50 mL saline once per day for 21 days.The national institutes of health stroke scale (NIHSS) scores of two groups were analyzed before and after the treatment. All patients were classified according to the trial of org 10 172 in acute stroke treatment (TOAST) classification and oxforshire community stroke project (OCSP) classification. Results: Before treatment, there was no significant difference in the NIHSS scores between the two groups(P>0.05). At the end of treatment, the NIHSS scores in both groups were significantly decreased(P<0.05). Compared with the control group, the treatment group had lower NIHSS scores(P<0.05). The efficacy in the treatment group(81.67％)was better than that in the control group(51.67％). The differences between diabetes, TOAST classification and clinical results were significant(P<0.05). Age, sex, hypertension, heart disease, hyperlipidemia, smoking, drinking alcohol, transient ischemic attack(TIA), progressive cerebral infarction, and OCSP classification had no significant effects on clinical results(P>0.05).The efficacy using HUK to patients without diabetes and non cardiac cerebral infarction was better than the patients with diabetes and cardiac cerebral infarction. Conclusion: HUK is an effective treatment for acute cerebral infarction, especially for acute cerebral infarction patients without diabetes and non cardiac cerebral infarction patients.

Received: 31 March 2013

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2013/V23/I4/350

[1]Cohen JE, Leker RR. Intravenous thrombolytic therapy for acute ischemic stroke［J］. N Engl J Med, 2011, 365(10):964-965.

［2］唐超刚, 李振东, 甄君, 等. 尤瑞克林治疗急性脑梗死效果的TOAST分型评价［J］. 中国医药指南, 2012, 10(10):401-403.

［3］Campbell DJ. The kallikreinkinin system in humans［J］.Clin Exp Pharmacol Physiol,2001,28(12):1060-1065.

［4］Xia CF, Yin H, Yao YY, et al. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis［J］. Hum Gene Ther, 2006,17(2):206-219.

［5］Chao J, Chao L. Experimental therapy with tissue kallikrein against cerebral ischemia［J］. Front Biosci, 2006,11(5):1323-1327.

［6］李晓莉, 侯永敏, 苗丕渠. 治疗急性脑梗死新药——凯力康［J］. 中国处方药, 2005,11(44):69-72.

［7］张灿飞, 陶文丹, 刘鸣, 等. 尤瑞克林治疗急性缺血性脑卒中随机对照试验的系统评价［J］. 中国循证医学杂志, 2012, 12(5):570-576.

［8］谢丽华, 侯敬天, 侯玉立. 尤瑞克林治疗急性脑梗死Meta分析［J］. 中国卒中杂志, 2011,6(4):287-296.

［9］中华神经科学会. 各类脑血管疾病诊断要点［J］. 中华神经科杂志, 1996, 29(6):379.

［10］谭盛, 陈健, 刘卉, 等. 尤瑞克林治疗急性前循环脑梗死的近期疗效和安全性研究［J］. 中华神经医学杂志, 2011,10(6):622-625.
［11］郭笑天. 尤瑞克林治疗急性前循环脑梗死的近期疗效和安全性探讨［J］. 中国医学创新, 2012,9(27):20-21.

［12］吉维忠, 范丽君, 郝文莉, 等. 尤瑞克林治疗急性后循环脑梗死33例疗效观察［J］. 中国实用医药, 2010,5(7):135-136.

［13］Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Inflammation in ischemic stroke subtypes［J］. Curr Pharm Des, 2012,18(28):4289-4310.

［14］Nagano H, Suzuki T, Hayashi M, et al. Effects of a human urinary kininogenase (SK-827) on cerebral microcirculation after glass bead-induced cerebral embolism in rabbits［J］. In Vivo, 1992,6(5):497-502.

［15］Liu L, Zhang R, Liu K, et al. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis／reperfusion-induced injury through the ERK1／2 pathway［J］. Exp Neurol, 2009,219(2):453-465.

［16］Su J, Tang Y, Zhou H, et al. Tissue kallikrein protects neurons from hypoxia／reoxygenationinduced cell injury through Homer1b／c［J］. Cell Signal, 2012,24(11):2205-2215.

［17］李晓蕾, 李菁晶, 李轶, 等. 缺血性卒中A-S-C-O分型、TOAST分型及CISS分型的信度检验［J］. 中国卒中杂志, 2011, 6(5):359-365.

［18］王挺刚, 胡玲玲, 孔亮, 等. 尤瑞克林联合胰岛素治疗进展性脑梗死合并高血糖患者的疗效［J］. 中国老年学杂志, 2011,31(17):3290-3291.